SubHero Banner

Bavencio® (avelumab) – New indication

May 9, 2017 – EMD Serono announced the FDA approval of Bavencio (avelumab) injection, for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Download PDF